Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is scheduled to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). Aurinia Pharmaceuticals had a negative net margin of 8,435.08% and a negative return on equity of 48.36%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. On average, analysts expect Aurinia Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of AUPH traded down $0.10 during midday trading on Monday, hitting $6.16. 12,411 shares of the company traded hands, compared to its average volume of 327,154. The firm has a 50 day simple moving average of $6.33. Aurinia Pharmaceuticals has a 52 week low of $5.06 and a 52 week high of $7.85. The stock has a market cap of $568.18 million, a PE ratio of -8.11 and a beta of 1.09.
Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. Finally, BidaskClub raised shares of Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $15.65.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: Correction
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.